La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Altimmune Gestione

Gestione criteri di controllo 2/4

Altimmune's Il CEO è Vipin Garg, nominato in Nov2018, e ha un mandato di 5.75 anni. la retribuzione annua totale è $ 5.48M, composta da 11.3% di stipendio e 88.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.41% delle azioni della società, per un valore di $ 1.90M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.1 anni e 5.9 anni.

Informazioni chiave

Vipin Garg

Amministratore delegato

US$5.5m

Compenso totale

Percentuale dello stipendio del CEO	11.3%
Mandato del CEO	5.8yrs
Proprietà del CEO	0.4%
Durata media del management	5.2yrs
Durata media del Consiglio di amministrazione	6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

Sep 17

We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely

Aug 06

Altimmune: NASH And Obesity At The End Of The COVID Tunnel

Jul 27

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Vipin Garg rispetto agli utili di Altimmune?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$101m
Mar 31 2024	n/a	n/a	-US$93m
Dec 31 2023	US$5m	US$620k	-US$88m
Sep 30 2023	n/a	n/a	-US$78m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$85m
Dec 31 2022	US$3m	US$580k	-US$85m
Sep 30 2022	n/a	n/a	-US$87m
Jun 30 2022	n/a	n/a	-US$97m
Mar 31 2022	n/a	n/a	-US$102m
Dec 31 2021	US$3m	US$566k	-US$97m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$1m	US$514k	-US$49m
Sep 30 2020	n/a	n/a	-US$43m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$815k	US$500k	-US$21m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$34m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$2m	US$44k	-US$42m

Compensazione vs Mercato: La retribuzione totale di Vipin ($USD 5.48M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.44M ).

Compensazione vs guadagni: La retribuzione di Vipin è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Vipin Garg (66 yo)

5.8yrs

Mandato

US$5,482,089

Compensazione

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Vipin Garg	President	5.8yrs	US$5.48m	0.41% $ 1.9m
Matthew Harris	Chief Medical Officer	5.2yrs	US$2.24m	0.078% $ 356.6k
Raymond Jordt	Chief Business Officer	1.7yrs	US$2.94m	0.021% $ 94.9k
Andrew Shutterly	Acting CFO	1.6yrs	Nessun dato	0.016% $ 73.6k
Bertrand Georges	Chief Technology Officer	7.3yrs	Nessun dato	Nessun dato
M. Roberts	Chief Scientific Officer	11.8yrs	US$1.41m	0.061% $ 280.3k
Tony Blandin	Vice President of Quality & Compliance Management	2.6yrs	Nessun dato	Nessun dato

5.2yrs

Durata media

65yo

Età media

Gestione esperta: Il team dirigenziale di ALT è esperto e expertise (durata media dell'incarico 5.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Vipin Garg	President	5.8yrs	US$5.48m	0.41% $ 1.9m
Mitchel Sayare	Independent Chairman	14.4yrs	US$119.68k	0.037% $ 170.6k
John Gill	Independent Director	20.1yrs	US$103.68k	0.0039% $ 17.9k
David Drutz	Independent Director	7.3yrs	US$109.68k	0.078% $ 359.2k
Philip Hodges	Independent Director	7.3yrs	US$115.68k	0.012% $ 56.5k
Klaus Schafer	Independent Director	7.3yrs	US$104.68k	0.013% $ 59.4k
Wayne Pisano	Independent Director	6.1yrs	US$108.68k	0.012% $ 55.0k
Diane Jorkasky	Independent Director	4.3yrs	US$95.68k	0% $ 0
Rohit Loomba	Member of Mash Scientific Advisory Board	2.2yrs	Nessun dato	Nessun dato
Michael Charlton	Member of Mash Scientific Advisory Board	2.2yrs	Nessun dato	Nessun dato
Mazen Noureddin	Member of Mash Scientific Advisory Board	2.2yrs	Nessun dato	Nessun dato
Naga Chalasani	Member of Mash Scientific Advisory Board	2.2yrs	Nessun dato	Nessun dato

6.0yrs

Durata media

72yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALT sono considerati esperti (durata media dell'incarico 5.9 anni).

Altimmune Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

President exercised options and sold US$115k worth of stock

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

President exercised options and sold US$106k worth of stock

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Recent updates

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Buy Altimmune's Potential Market Disruption With Pemvidutide

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

President exercised options and sold US$115k worth of stock

Thoroughly Derisked, Altimmune Is Now A Great Buy

Price target increased by 11% to US$21.29

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 29%

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Consensus revenue estimates increase by 11%

Price target decreased by 21% to US$19.38

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Price target decreased by 11% to US$26.25

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 11% to US$26.25

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

President exercised options and sold US$106k worth of stock

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Independent Director exercised options and sold US$248k worth of stock

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Reassessing Altimmune

Altimmune sets new 52-week high on rising volume

Consensus forecasts updated

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Price target increased to US$24.86

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune Q2 2022 Earnings Preview

Altimmune, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Chief Scientific Officer exercised options and sold US$369k worth of stock

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Independent Director recently bought US$5.4k worth of stock

Consensus forecasts updated